Received Feb 6, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TDAP | TDAP (BOOSTRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | E9X9A | — |
Drug Exposure During Pregnancy; 2nd dose of boostrix was administered; This non-serious prospective pregnancy case was reported by a nurse via call center representative and described the occurrence of vaccine exposure during pregnancy in a 19-year-old female patient who received DTPa (Reduced antigen) (Boostrix) (batch number E9X9A, expiry date 16-JUN-2028) for prophylaxis. Co-suspect products included DTPa (Reduced antigen) (Boostrix) (batch number E9X9A, expiry date 16-JUN-2028) for prophylaxis. On 28-JAN-2026, the patient received the 2nd dose of Boostrix. On 06-JAN-2026, the patient received the 1st dose of Boostrix. On 28-JAN-2026, an unknown time after receiving Boostrix and not applicable after receiving Boostrix, the patient experienced extra dose administered (Verbatim: 2nd dose of boostrix was administered). On an unknown date, the patient experienced vaccine exposure during pregnancy (Verbatim: Drug Exposure During Pregnancy). The outcome of the vaccine exposure during pregnancy and extra dose administered were not applicable. Pregnancy exposure: Pregnancy Exposure (Boostrix): Trimester unknown Pregnancy Exposure (Boostrix): Trimester unknown Pregnancy Outcome: Pregnancy was ongoing This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt date: 28-JAN-2026 A registered nurse called in to request data about the administration of 2 doses of Boostrix to a pregnant patient, 22 days apart during the same gestation.